Opioid Use Disorders Market to Reach USD 8.8 Billion by 2034, Expanding at 9.9% CAGR Amid Rising Opioid Addiction and Treatment Awareness

The global opioid use disorders market was valued at US$ 3.2 Bn in 2023 and is projected to reach US$ 8.8 Bn by 2034, expanding at a CAGR of 9.9% from 2024 to 2034. Market growth is primarily driven by increasing investment and funding from governments and non-government agencies worldwide to control opioid overdose and address the growing prevalence of opioid use disorder.

The rising incidence of opioid addiction is increasing the need for medication-assisted treatment and other approaches to opioid dependence management. Companies operating in the market are working toward increasing the production of buprenorphine hydrochloride and naloxone hydrochloride sublingual tablets, which are generic versions of Suboxone used for treating opioid addiction.

Market participants are also exploring the use of naloxone nasal sprays as part of harm reduction therapy for emergency treatment of suspected or known opioid overdose. Increasing emphasis on improving access to treatment, creating awareness, and reducing the consequences of opioid misuse is supporting market expansion.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=75167

Opioid Use Disorders Market Overview

Opioid use disorder is a serious health issue worldwide, creating substantial demand for treatment options that can help individuals battling opioid dependence. Several medication-assisted treatment options are available, with naltrexone, buprenorphine, and methadone representing key products used in treatment.

The opioid crisis has consequences that extend beyond addiction itself. These include an increasing frequency of blood-borne infections and proliferation of bacteria that can cause heart infections such as endocarditis. The growing health burden associated with opioid misuse is encouraging governments, healthcare organizations, and pharmaceutical companies to expand treatment and harm-reduction efforts.

Organic growth strategies are being emphasized by companies operating in the industry. In April 2020, Amneal Pharmaceuticals, Inc. announced that it had received U.S. FDA approval of an abbreviated new drug application for a generic version of the Butrans transdermal system. The company received competitive generic therapy designation with 180 days of exclusivity for the 7.5 mcg/hr dose.

Government funding is also contributing to the treatment landscape. In August 2022, the U.S. Department of Health and Human Services announced the award of US$ 79.1 Mn in overdose prevention grants as part of the National Drug Control Strategy, HHS Overdose Prevention Strategy, and Biden-Harris Unity Agenda to address the opioid overdose epidemic.

Growing Cases of Opioid Addiction Propelling Treatment Demand

The rising incidence of opioid addiction is a major factor driving the opioid use disorders market. According to the World Health Organization, nearly 296 million individuals worldwide used drugs at least once during 2021, while close to 39.5 million individuals were fighting drug disorders during the same year.

The burden of opioid use is also significant in India. According to the Magnitude of Substance Use in India published by the National Drug Dependence Treatment Centre in February 2019, the incidence of opioid use was 2.1%, with approximately 0.6% of Indians expected to require help for problems associated with opioid use.

In the U.S., the Centers for Disease Control and Prevention reported that 2.7 million people aged 12 and above suffered from opioid use disorders. The presence of a substantial patient population is creating a continued need for medications and treatment programs designed to address opioid dependence.

Increasing prevalence is therefore accelerating demand for medication-assisted treatment and other opioid misuse treatment approaches. Pharmaceutical companies are focusing on products that can improve access to treatment, while healthcare agencies are emphasizing early intervention, overdose prevention, and support for individuals affected by opioid dependence.

Government and Non-government Agencies Increasingly Focusing on Awareness

Government and non-government organizations are increasingly organizing awareness campaigns focused on the harmful effects of drug overdose. The rising number of individuals affected by opioid addiction has prompted stakeholders to adopt broader approaches toward addressing drug abuse and reducing the impact of opioid dependence.

Various countries have introduced initiatives aimed at assisting patients and expanding access to treatment. These efforts are supporting awareness regarding opioid addiction while also encouraging the adoption of medication-assisted treatment.

In March 2022, the U.S. Department of Health and Human Services announced funding for opioid use prevention and treatment. The initiative was intended to expand access to medication-assisted treatment for opioid use disorder and support the prevention of prescription drug misuse.

Continued government and non-government efforts to educate populations about the consequences of opioid addiction are therefore contributing to market development. Awareness initiatives can also encourage individuals affected by opioid dependence to seek treatment and increase access to available therapies.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=75167

Regional Analysis of Opioid Use Disorders Market

North America dominated the global opioid use disorders market in 2023 and is expected to maintain its leading position throughout the forecast period. The region's dominance is attributed to the sizable number of individuals battling opioid dependency, particularly in the U.S., along with continued government and healthcare-sector efforts to address opioid misuse.

The region has also witnessed substantial activity surrounding treatment access, overdose prevention, and medication-assisted treatment. Government agencies have introduced funding and treatment initiatives, while pharmaceutical companies continue to develop and commercialize products for opioid use disorder.

Asia Pacific represents another significant market. Growth in the region is associated with increasing awareness regarding opioid addiction and rising healthcare expenditure. Greater awareness of substance use disorders is supporting development of the narcotic use disorder treatment landscape, while increasing healthcare spending is contributing to the availability of treatment services.

The expansion of treatment awareness and healthcare infrastructure across Asia Pacific is expected to create further opportunities for companies operating in the opioid use disorders market.

Competitive Landscape

Key participants in the opioid use disorders market are focusing on product launches, treatment accessibility, and strategies designed to strengthen their market positions. Companies are also working to expand the availability of medications used in opioid dependence treatment and overdose prevention.

In April 2023, the New York State Department of Health and New York State Office of Addiction Services and Supports announced the launch of the Buprenorphine Assistance Pilot Program. The program was designed to help optimize the price of buprenorphine used for treatment of opioid use disorders.

Indivior PLC, Alkermes plc, Orexo AB, Titan Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International, Inc., Viatris Inc. (Mylan N.V.), Hikma Pharmaceuticals plc, and Camurus AB are among the key companies covered in the opioid use disorders market report.

These companies are profiled based on company overview, business strategies, financial overview, product portfolio, and business segments. Competitive activity is centered on expanding treatment options, improving access to opioid dependence therapies, and strengthening product portfolios.

Opioid Use Disorders Market Segmentation

The global opioid use disorders market is segmented by drug type, route of administration, and distribution channel. Based on drug type, the market comprises buprenorphine, methadone, and naltrexone. These medications form an important part of medication-assisted treatment approaches for opioid use disorder.

By route of administration, the market is divided into oral and parenteral. The availability of different administration routes provides treatment providers with options based on the therapy and patient requirements.

Based on distribution channel, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. These channels play an important role in facilitating access to opioid use disorder medications.

The market analysis covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Countries covered include the U.S., Canada, Germany, the U.K., France, Italy, Spain, China, India, Japan, Australia & New Zealand, Brazil, Mexico, South Africa, and GCC countries.

Market Outlook

The global opioid use disorders market is expected to witness strong growth through 2034 as the prevalence of opioid addiction, demand for treatment, government funding, and awareness initiatives continue to shape the industry.

The market is projected to increase from US$ 3.2 Bn in 2023 to US$ 8.8 Bn by 2034, representing a CAGR of 9.9% during the forecast period. Increasing emphasis on medication-assisted treatment, greater availability of buprenorphine, methadone, and naltrexone, and exploration of naloxone nasal sprays for emergency overdose treatment are supporting the evolution of the treatment landscape.

North America is expected to remain the dominant regional market, while growing awareness and healthcare spending are supporting opportunities in Asia Pacific. Continued involvement of government and non-government agencies in overdose prevention, treatment access, and public awareness is likely to remain a central factor shaping the future development of the opioid use disorders industry.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=75167<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Topical Antibiotics Market

Human Papillomavirus Vaccine Market

Allergy Immunotherapy Market

Protein Therapeutics Market

Next-Generation Immunotherapies Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com